JAZZ Jazz Pharmaceuticals plc

119.65
-1.48  -1%
Previous Close 121.13
Open 120.88
Price To Book 2.27
Market Cap 6,774,719,281
Shares 56,621,139
Volume 526,611
Short Ratio
Av. Daily Volume 501,069
Stock charts supplied by TradingView

NewsSee all news

  1. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to

  2. Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans

    DUBLIN, Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders

  3. Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

    DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and

  4. Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

    DUBLIN, Aug. 27, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Wells Fargo Securities

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released March 26, 2019 met primary endpoint.
PF743 (JZP-458)
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
JZP-6
Fibromyalgia
Phase 2 enrollment initiation announced February 8, 2017.
JZP-110
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Xyrem
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
JZP-110
Excessive sleepiness associated with obstructive sleep apnea
FDA Approval announced March 20, 2019.
JZP-110
Excessive sleepiness associated with narcolepsy
Phase 3 timing of interim analysis due 2019.
Defibrotide
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Vyxeos
Acute myeloid leukemia
Phase 2 enrolment to be completed 2019.
Defibrotide
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
JZP-258
Idiopathic Hypersomnia
Phase 1/2 presentation at ASCO May 31, 2019.
CPX-351
Acute myeloid leukemia (AML)
Phase 1b data due 2H 2019.
Vyxeos in combination with venetoclax
First-line unfit Acute myeloid leukemia
Phase 2/3 trial to be initiated later in 2019.
JZP-458
Acute lymphoblastic leukemia (ALL)
Phase 2 commencement of enrolment announced October 10, 2019.
Defibrotide
CAR-T associated neurotoxicity in diffuse large B-cell lymphoma (DLBCL) patients

Latest News

  1. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity

    DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the first patient has been enrolled in an exploratory Phase 2 clinical trial evaluating the ability of defibrotide to

  2. Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans

    DUBLIN, Sept. 30, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the results of a consumer survey of more than 1,000 Americans measuring public perception and knowledge of sleep disorders

  3. Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

    DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and

  4. Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

    DUBLIN, Aug. 27, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Wells Fargo Securities